See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
US Politics
Republican Party
Democratic Party
Trade War
Donald Trump
Tariffs
Senate
Social Media
US Economy
Natural Disasters
Holi
European Union
Published • loading... • Updated

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE)

Summary by Benzinga
Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer. The results of the trial, released Monday, included estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer patients whose disease progressed follow…

10 Articles

All
Left
Center
2
Right
1
Investor's Business DailyInvestor's Business Daily

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug. The post Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug appeared first on Investor's Business Daily.

Read Full Article
BenzingaBenzinga

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE)

Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer. The results of the trial, released Monday, included estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer patients whose disease progressed follow…

·New York, United States
Read Full Article
STATSTAT

Diseased protein degrader shows mixed results in breast cancer trial

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression more than 40% for an ESR1-mutated population, but not for a broader group.

·Boston, United States
Read Full Article
Inside Precision MedicineInside Precision Medicine

Mixed Phase III Results for Arvinas, Pfizer's Breast Cancer PROTAC Degrader

Phase III results were announced for Arvinas and Pfizer’s first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader this week showing it was only effective in people with advanced or metastatic breast cancer with an estrogen receptor 1-mutant in their tumor. Although the drug, vepdegestrant, met its primary endpoint in the population with an estrogen receptor 1-mutant, it did not meet this goal in the larger “intenti…

Read Full Article
Pharmacy TimesPharmacy Times

Vepdegestrant Demonstrates Progression-Free Survival in Patients With ER+/HER2- Metastatic Breast Cancer

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

Read Full Article
curetoday.comcuretoday.com

Vepdegestrant May Reduce Disease Progression in Breast Cancer Subset

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States on Tuesday, March 11, 2025.
Sources are mostly out of (0)

Similar News Topics

Breast Cancer

Breast Cancer

Stock Markets

Stock Markets

Technology

Technology

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal